Other studies have shown that the expression of immune checkpoint molecules such as PD-1, PD-L1, and CTLA-4 can vary significantly across different cell populations within the tumor, highlighting the complexity of immune regulation in the TME [46]. This evidence concerns the gene CTLA4 and neoplasm.